Crossmark

Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters

Crossref DOI link: https://doi.org/10.1038/s41564-022-01170-4

Published Online: 2022-06-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Uraki, Ryuta https://orcid.org/0000-0003-0890-1922
Kiso, Maki

Imai, Masaki https://orcid.org/0000-0001-6988-1975
Yamayoshi, Seiya https://orcid.org/0000-0001-7768-5157
Ito, Mutsumi

Fujisaki, Seiichiro

Takashita, Emi https://orcid.org/0000-0002-9064-4699
Ujie, Michiko

Furusawa, Yuri

Yasuhara, Atsuhiro

Iwatsuki-Horimoto, Kiyoko https://orcid.org/0000-0002-8266-020X
Sakai-Tagawa, Yuko

Watanabe, Shinji

Hasegawa, Hideki

Kawaoka, Yoshihiro https://orcid.org/0000-0001-5061-8296
Funding

Funding for this research was provided by:

Japan Agency for Medical Research and Development (JP21fk0108615, JP20fk0108472, JP20nk0101632, JP21wm0125002, JP20fk0108412)

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201400008C, 75N93021C00014)

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
License Information

Text and Data Mining valid from 2022-06-15

Version of Record valid from 2022-06-15
More Information

Article History

Received: 7 January 2022

Accepted: 1 June 2022

First Online: 15 June 2022

Competing interests

: Y.K. has received unrelated funding support from Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns Laboratories, Inc., Shionogi & Co. LTD, Otsuka Pharmaceutical, KM Biologics, Kyoritsu Seiyaku, Shinya Corporation and Fuji Rebio. All other authors declare no competing interests.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below